The Following Is How To Check The Status Of Ami Organics IPO Share Allocation.
Ami Organics IPO: The public offering includes a re-issuance of 200 million rupees and an offer of 370 million rupees to be sold by 20 shareholders.
Ami Organics will complete its initial public offering (IPO) share allocation of 5.7 billion rupees tomorrow ( 8 September). The Ami Organics IPO, which was publicly tendered from September 1st to 3rd, received 64.54 times of subscription. Qualified institutional investors partially subscribed 86.64 times, and non-institutional investors subscribed 154.81 times.
The public offering includes a newly issued 200 million rupees and an offer of 370 million rupees to be sold by 20 shareholders. The proceeds from the initial public offering will be used to repay debt and meet working capital needs.
Ami Organics develops, manufactures and sells advanced pharmaceutical intermediates for the manufacture of Active Pharmaceutical Ingredients (APsI) and New Chemical Entities (NCE) in India and abroad.
Here’s how to check the share allotment status of Ami Organics IPO:
Link Intime India website
- Login into the Link Intime India website
- Select Ami Organics IPO
- Select either Application Number, DPID/Client ID or PAN (Let’s take application number)
- Enter your IPO application number
- Fill Captcha
- Click on the ‘Submit’ button
BSE website
- Log into BSE link – bseindia.com/investors/appli_check.aspx
- Select Ami Organics IPO
- Enter your Ami Organics IPO application number
- Enter your PAN card details
- Click ‘I’m not a robot’
- Click on the ‘Submit’ button
NEW DELHI: The Supreme Court directed Vodafone India to deposit Rs 2,000 crore with the department of telecommunications, paving the Read more
The Initial Public Offer (IPO) of ICICI Prudential Life Insurance Company Ltd — a first by an insurance entity — Read more
IRCTC has offered conveyance of rail tickets enabling travelers to make installment through any installment mode, including money. Expansive basing Read more
The proposal is unlikely to be challenged because all other existing investors, including Jack Ma’s Alibaba and subsidiaries that own Read more
